F
Frank J. Beurskens
Researcher at Genmab
Publications - 87
Citations - 5059
Frank J. Beurskens is an academic researcher from Genmab. The author has contributed to research in topics: Antibody & Complement system. The author has an hindex of 29, co-authored 82 publications receiving 4375 citations. Previous affiliations of Frank J. Beurskens include Utrecht University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Fc receptor but not complement binding is important in antibody protection against HIV
Ann J. Hessell,Lars Hangartner,Meredith Hunter,Carin E. G. Havenith,Frank J. Beurskens,Joost M. Bakker,Caroline Lanigan,Gary Landucci,Donald N. Forthal,Paul W. H. I. Parren,Preston A. Marx,Dennis R. Burton +11 more
TL;DR: There is a dramatic decrease in the ability of a broadly neutralizing antibody to protect macaques against SHIV challenge when Fc receptor and complement-binding activities are engineered out of the antibody.
Journal ArticleDOI
Complement is activated by IgG hexamers assembled at the cell surface.
Christoph A. Diebolder,Christoph A. Diebolder,Frank J. Beurskens,Rob N. de Jong,Roman I. Koning,Kristin Strumane,Margaret A. Lindorfer,Marleen Voorhorst,Deniz Ugurlar,Sara Rosati,Albert J. R. Heck,Jan G. J. van de Winkel,Ian A. Wilson,Abraham J. Koster,Ronald P. Taylor,Erica Ollmann Saphire,Dennis R. Burton,Dennis R. Burton,Janine Schuurman,Piet Gros,Paul W. H. I. Parren +20 more
TL;DR: This work found that specific noncovalent interactions between Fc segments of immunoglobulin G (IgG) antibodies resulted in the formation of ordered antibody hexamers after antigen binding on cells, thereby triggering the complement cascade.
Journal ArticleDOI
Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study
Bo Baslund,Niels Tvede,Bente Danneskiold-Samsøe,Per Larsson,Gabriel S. Panayi,Joergen Petersen,Lars Jelstrup Petersen,Frank J. Beurskens,Janine Schuurman,Jan G. J. van de Winkel,Paul W. H. I. Parren,J. Alastair Gracie,Sarah L. Jongbloed,Foo Y. Liew,Iain B. McInnes +14 more
TL;DR: Clinical data suggest for the first time that IL-15 could represent a novel therapeutic target in RA and HuMax-IL15 was well tolerated clinically, with no significant effects on T lymphocyte subset and natural killer cell numbers.
Journal ArticleDOI
Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Andrew W. Pawluczkowycz,Frank J. Beurskens,Paul V. Beum,Margaret A. Lindorfer,Jan G. J. van de Winkel,Paul W. H. I. Parren,Ronald P. Taylor +6 more
TL;DR: The role of C1q in the dynamics of complement activation and CDC of B cell lines and primary cells from patients with chronic lymphocytic leukemia, reacted with OFA or RTX is examined.
Patent
Recombinant monovalent antibodies and methods for production thereof
Paul W. H. I. Parren,Janine Schuurman,Tom Vink,Willem Karel Bleeker,Jan G. J. van de Winkel,Patrick Van Berkel,Frank J. Beurskens +6 more
TL;DR: In this article, the authors presented a method of making monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalents, pharmaceutical compositions comprising such antibodies, and uses of the monovalant antibodies.